Virpax Pharmaceuticals Inc
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an … Read more
Virpax Pharmaceuticals Inc (VRPX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: 3.142x
Based on the latest financial reports, Virpax Pharmaceuticals Inc (VRPX) has a cash flow conversion efficiency ratio of 3.142x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.87 Million) by net assets ($-913.76K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Virpax Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Virpax Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Virpax Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Virpax Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dong Ah Tire & Rubber Co. Ltd.
KQ:007340
|
N/A |
|
New Mountain Finance Corporation 8.250% Notes due 2028
NASDAQ:NMFCZ
|
N/A |
|
Lang & Schwarz Aktiengesellschaft
XETRA:LUS1
|
0.009x |
|
MGO Global Inc. Common Stock
NASDAQ:MGOL
|
-0.567x |
|
KARELIAN DIA.R. EO-00025
F:KJY1
|
N/A |
|
Abacus Life Inc. 9.875% Fixed Rate Senior Notes due 2028
NASDAQ:ABLLL
|
0.014x |
|
PROGRESS-WERK (PWO.SG)
STU:PWO
|
0.104x |
|
Orlen SA
PR:ORLEN
|
N/A |
Annual Cash Flow Conversion Efficiency for Virpax Pharmaceuticals Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Virpax Pharmaceuticals Inc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-913.76 Million | $-16.71 Billion | 18.290x | +459.04% |
| 2023-12-31 | $1.93 Million | $-9.85 Million | -5.094x | -373.23% |
| 2022-12-31 | $16.58 Million | $-17.85 Million | -1.076x | -177.47% |
| 2021-12-31 | $37.48 Million | $-14.54 Million | -0.388x | -218.11% |
| 2020-12-31 | $-4.22 Million | $-1.38 Million | 0.328x | -20.71% |
| 2019-12-31 | $-2.73 Million | $-1.13 Million | 0.414x | -72.55% |
| 2018-12-31 | $-1.19 Million | $-1.80 Million | 1.509x | -- |